Welcome to our dedicated page for Arcus Bioscience SEC filings (Ticker: RCUS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arcus Biosciences, Inc. (NYSE: RCUS) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company focused on oncology and inflammatory and autoimmune diseases, Arcus uses SEC filings to report material clinical, financial and corporate events that can be important for investors analyzing RCUS stock.
Form 8‑K current reports frequently highlight significant developments in Arcus’s pipeline and capital structure. For example, 8‑K filings describe the discontinuation of the Phase 3 STAR‑221 trial and the Phase 2 EDGE‑Gastric study after an interim overall survival analysis showed no benefit for the domvanalimab plus zimberelimab and chemotherapy regimen compared with nivolumab plus chemotherapy. Other 8‑Ks detail updated data from the ARC‑20 Phase 1/1b study of casdatifan in metastatic clear cell renal cell carcinoma, including progression-free survival and response metrics, as well as safety findings.
Filings also cover financing and capital markets transactions. One Form 8‑K outlines an underwriting agreement for a public offering of common stock, including the number of shares sold, pricing and net proceeds. Another 8‑K describes a First Amendment to the company’s Loan and Security Agreement with Hercules Capital and other lenders, which restructures remaining term loan commitments into milestone-based tranches tied to Phase 3 data and potential FDA approval, extends the maturity date and adds performance covenants linked to market capitalization, qualified cash levels and potential net product revenue thresholds.
Investors can also use SEC filings to track collaboration and licensing arrangements, such as disclosures related to Arcus’s long-term collaboration with Gilead Sciences and its option and license agreement with Taiho Pharmaceutical. These documents may reference option exercises, milestone structures and rights to co-develop or commercialize investigational medicines like casdatifan, domvanalimab, zimberelimab and quemliclustat in specific territories.
Stock Titan’s interface surfaces these filings alongside AI-powered summaries that explain the practical implications of each document. Instead of parsing detailed legal language alone, readers can review concise explanations of how a loan amendment changes Arcus’s access to capital, what a trial discontinuation means for a particular program, or how a new data disclosure from a Phase 1/1b or Phase 3 study might influence the company’s development strategy. Real-time updates from EDGAR, combined with these AI insights, help users follow Arcus’s quarterly results, material clinical events, financing decisions and collaboration milestones directly from the underlying SEC record.
Arcus Biosciences (RCUS) Form 144 summary: The notice reports a proposed sale of 2,831 common shares through Morgan Stanley Smith Barney on 09/29/2025 with an aggregate market value of $36,350.04. The shares were acquired as restricted stock units on 12/15/2024 and the filing shows the acquisition and payment date as 12/15/2024. The form also discloses a prior sale during the past three months: a 10b5-1 sale by Alexander Azoy of 1,579 shares on 09/05/2025 for gross proceeds of $18,758.05. The filer certifies they are not aware of undisclosed material adverse information and notes Rule 10b5-1 plan considerations where applicable.
Arcus Biosciences insider sale by Chief Accounting Officer. Alexander Azoy, listed as Chief Accounting Officer, reported a sale of 1,579 shares of Arcus Biosciences (RCUS) on 09/05/2025. The filing shows these shares were originally purchased on 05/30/2025 through the company Employee Stock Purchase Plan and were sold under a Rule 10b5-1 trading plan adopted 06/06/2025. The weighted-average sale price reported is $11.8797, with individual sale prices ranging from $11.55 to $12.22. After the reported sale, the reporting person beneficially owned 30,194 shares directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Arcus Biosciences, Inc. (RCUS) notice reports a proposed sale of 1,579 common shares acquired under an Employee Stock Purchase Plan on 05/31/2025. The shares have an aggregate market value of $18,253.24 and the issuer has 106,430,976 shares outstanding. The sale is to be executed through Morgan Stanley Smith Barney LLC on the NYSE with an approximate sale date of 09/05/2025. Payment for the acquisition was cash. The filer states there were no securities sold by the person in the past three months and includes the standard representation that the seller is not aware of undisclosed material adverse information.